BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Mar 22, 2004
 |  BioCentury  |  Emerging Company Profile

Algodign: From Russia with data

When he co-founded Protein Design Labs Inc., Cary Queen brought to the company the idea of using computer modeling to improve proteins - antibodies in the case of PDLI. Now, as chairman of Algodign Inc., he's expanding the idea to small molecules. Although not the first company to use computer-based drug design, Algodign believes its software offers advantages compared to competing technologies, because it does not require co-crystal structures of compounds bound to proteins. In addition, the software generates compounds that can be manufactured readily.

Queen essentially runs Algodign on his own nickel - he is funding the company with proceeds from the sale of his stock in PDLI (Fremont, Calif.). As a result, Queen is determined to maintain a lean organization and accordingly has...

Read the full 614 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >